A majority of states will legalize psychedelics by 2037, according to a new analysis published in an American Medical Association journal that’s based on a statistical model of the state-level marijuana legalization movement.
Psychedelics reform has been advancing “in a rapid, patchwork fashion” in the U.S.—and while the decriminalization movement started in more liberal states, “psychedelic drug reform is becoming a bipartisan issue,” the study, published in the Journal of the American Medical Association (JAMA) Psychiatry on Wednesday, found.
Researchers at Washington University in St. Louis compiled and analyzed data on psychedelics legislation that’s been introduced and enacted in cities and state legislatures across the country, as well as ballot initiatives on the issue, from 2019 to 2022.
Starting with Denver’s historic move to decriminalize psilocybin in May 2019, the psychedelics renaissance has exploded in recent years, taking the form of proposals to end criminalization, promote research and legalize it for therapeutic uses, as Oregon voters elected to do at the ballot in 2020. Colorado followed up last month with a voter-approved initiative to legalize possession of a wide range of psychedelics by adults while setting up “healing centers” for psilocybin.